Literature DB >> 6190926

Monoclonal cytotoxic T lymphocyte hybridomas capable of specific killing activity, antigenic responsiveness, and inducible interleukin secretion.

Y Kaufmann, G Berke.   

Abstract

We have recently described the production of cytotoxic T lymphocyte (CTL) hybridomas that grow continuously in culture, exhibiting constitutive, allospecific (anti-H-2b) killing activity. We now report on the response of these monoclonal CTL hybridomas to specific antigen (H-2Db) and to mitogenic lectins. Both specific antigen and T cell mitogens enhance hybridoma-mediated specific target cell killing. In addition, stimulated, but not unstimulated hybridoma cells secrete considerable amounts of IL 2 into the culture medium. Repeated cloning of the hybridomas provides strong evidence that both killing activity and IL 2 secretion can be attributed to one cell. Unfractionated Con A supernatants, containing IL 2 and other factors known to influence T cell responsiveness, or IL 2-containing media of stimulated hybridomas affect neither the growth nor the lytic activity of the hybridomas. Anti-LFA-1 monoclonal antibody, a potent inhibitor of CTL and CTL hybridoma-mediated target cell lysis, abolishes antigen- or mitogen-induced IL 2 secretion by the CTL hybridomas. Involvement of a single hybridoma receptor in antigen recognition (afferent and efferent) and in initiating IL 2 secretion is proposed. The CTL hybridomas displaying retarded killing activity before the antigenic or mitogenic stimulation appear to represent an intermediate stage in CTL differentiation, reminiscent of "memory" CTL.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6190926

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Inducible functions in hybrids of a Lyt-2+ BW5147 transfectant and the 2C CTL line.

Authors:  J J Gu; P D Gottlieb
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

2.  AKR murine thymic leukemias are from a distinct thymic cell lineage and do not express the beta chain of the T-cell antigen receptor.

Authors:  F L Owen; W M Strauss; C Murre; A D Duby; H Hiai; J G Seidman
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

3.  Rearrangement and transcription of a T-cell receptor beta-chain gene in different T-cell subsets.

Authors:  S M Hedrick; R N Germain; M J Bevan; M Dorf; I Engel; P Fink; N Gascoigne; E Heber-Katz; J Kapp; Y Kaufmann
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

4.  Differential susceptibility of mouse Lyt-2 and Lyt-3 genes to negative regulation.

Authors:  I Hwang; J J Gu; P D Gottlieb
Journal:  Immunogenetics       Date:  1993       Impact factor: 2.846

5.  Class II-restricted bifunctional T-cell hybridomas reactive to self- and foreign myelin basic protein.

Authors:  D C Rayner; L D Petrycky
Journal:  Immunology       Date:  1990-07       Impact factor: 7.397

6.  Mechanism of lymphocyte-mediated cytolysis: functional cytolytic T cells lacking perforin and granzymes.

Authors:  G Berke; D Rosen; D Ronen
Journal:  Immunology       Date:  1993-01       Impact factor: 7.397

7.  High activity of N-alpha-benzyloxycarbonyl-L-lysine thiobenzyl ester serine esterase and cytolytic perforin in cloned cell lines is not demonstrable in in-vivo-induced cytotoxic effector cells.

Authors:  G Dennert; C G Anderson; G Prochazka
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

8.  Resistance of cytolytic lymphocytes to perforin-mediated killing. Induction of resistance correlates with increase in cytotoxicity.

Authors:  C C Liu; S Jiang; P M Persechini; A Zychlinsky; Y Kaufmann; J D Young
Journal:  J Exp Med       Date:  1989-06-01       Impact factor: 14.307

Review 9.  Phenotypic changes in growth-arrested T cell hybrids: a possible avenue to produce functional T cell hybridoma.

Authors:  Koichi Kubota; Kazuya Iwabuchi
Journal:  Front Immunol       Date:  2014-05-19       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.